Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -91.9%. (2009–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $330157 | $2M | $3M | $2M | $6M | $33M | $31M | $76M | $31M | $27M | $11M |
| Enterprise Value | $936157 | $2M | $3M | $18M | $13M | $45M | $49M | $93M | $36M | $6M | $7M |
| P/E Ratio → | -0.07 | — | 0.56 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.25 | 1.27 | 4.11 | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.07 | 0.21 | 0.27 | — | — | 33.78 | — | — | — | 1.67 | 1.70 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.73 | 4.29 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | 17.85 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 21.52 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -202.3% | -202.3% | -88.1% | — | — | — | — | — | — | — | — |
| Operating Margin | -575.3% | -575.3% | -1312.8% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -633.6% | -633.6% | 728.9% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -91.9% | -91.9% | 177.4% | — | — | -835.6% | — | — | -600.0% | -87.0% | -31.2% |
| ROA | -66.3% | -66.3% | 31.0% | -29.2% | -19.6% | -33.0% | -5.4% | -102.3% | -90.6% | -63.5% | -25.9% |
| ROIC | -60.1% | -60.1% | -61.1% | -86.5% | -89.5% | -62.1% | 29.5% | — | — | — | -178.8% |
| ROCE | -69.6% | -69.6% | -63.2% | -48.0% | -40.7% | -79.6% | 17.7% | -89.9% | -93.7% | -47.0% | -35.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.21 | — | — | 29.77 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | 7.60 | — | — | — | — |
| Net Debt / Equity | — | 0.07 | 0.01 | — | — | 12.08 | — | — | — | -1.27 | -0.61 |
| Net Debt / EBITDA | — | — | — | — | — | — | 6.53 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -22.14 | -22.14 | -6.00 | -1216.44 | -2.19 | -3.23 | 6.54 | -5.30 | -5.45 | -332.39 | -30890.00 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.30 | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 |
| Quick Ratio | 1.30 | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 |
| Cash Ratio | 1.05 | 1.05 | 1.09 | 2.74 | 6.02 | 7.11 | 0.15 | 3.82 | 3.48 | 10.37 | 18.42 |
| Asset Turnover | — | 0.11 | 0.05 | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 46.77 | 120.37 | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 179.1% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $806368 | $390657 | $188519 | $141144 | $110815 | $81663 | $65355 | $50258 | $33774 |
Imminent liquidity and dilution
Based on reported figures, SCNI trades at a price-to-sales ratio of 0.25, which suggests the market is heavily discounting the company's future revenue potential and valuing the firm primarily as a distressed entity rather than a high-growth biotechnology platform with proprietary NanoAb assets.
The low P/S multiple relative to broader biotech peers indicates that investors are skeptical of the company's ability to monetize its Jerusalem-based manufacturing facility. This valuation appears to ignore the potential replacement cost of the physical infrastructure, suggesting that the market is currently pricing in a high probability of further equity dilution or operational failure.
As reported in financial statements, SCNI's ROIC has fluctuated significantly, reaching -17.3% in 2026Q1, which underscores the company's ongoing struggle to generate meaningful returns on its invested capital while maintaining a high-cost, underutilized biologics manufacturing facility in a competitive regional market.
The volatility in return metrics suggests that the company's capital allocation is currently driven by survival-based funding rounds rather than organic compounding of assets. Investors should monitor whether the pivot to NanoAb development can eventually drive a positive shift in ROIC, as current levels indicate significant value destruction relative to the capital deployed.
According to recent quarterly data, the company's asset turnover ratio remains extremely low at 0.03, reflecting the inherent difficulty of scaling a boutique CDMO service model within a capital-intensive facility that has yet to achieve sufficient throughput to cover its fixed operating costs.
The extended and erratic nature of the cash conversion cycle, evidenced by high days payable outstanding, suggests that the company is managing liquidity by stretching supplier terms. This reliance on vendor financing may indicate underlying pressure on cash reserves and warrants further investigation into the sustainability of current operational partnerships.
Based on the provided figures, SCNI's debt-to-equity ratio of 0.30 as of 2026Q1 represents a significant improvement from historical peaks, yet the negative interest coverage ratio of -22.03 suggests that the firm lacks the operational cash flow necessary to service its existing debt obligations independently.
While the reduction in leverage is a positive development, the company's reliance on external capital to meet interest payments remains a critical vulnerability. The current debt structure appears to be a stop-gap measure, and any further tightening in credit markets could severely limit the company's ability to refinance its obligations.
Investors frequently misapply the price-to-book ratio to SCNI, failing to recognize that the company's book value is heavily skewed by the carrying cost of its Jerusalem manufacturing facility, which may not reflect the true market value or utility of the assets in a liquidation scenario.
Relying on P/B ratios obscures the reality that the firm's primary value lies in its intangible IP and the potential for future clinical milestones, rather than its physical plant. Analysts should instead focus on cash runway and burn rate metrics, as these provide a more accurate assessment of the company's survival prospects than static balance sheet valuations.
Includes 30+ ratios · 17 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SCNI stock.
Scinai Immunotherapeutics Ltd.'s current P/E ratio is -0.1x. The historical average is 0.6x.
Scinai Immunotherapeutics Ltd.'s return on equity (ROE) is -91.9%. The historical average is -23.4%.
Based on historical data, Scinai Immunotherapeutics Ltd. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
Scinai Immunotherapeutics Ltd. has -202.3% gross margin and -575.3% operating margin.